Vertex Pharmaceuticals (VRTX) Asset Writedowns and Impairment (2009 - 2025)
Vertex Pharmaceuticals (VRTX) posted Asset Writedowns and Impairment of $379.0 million for Q1 2025, up 4481.5% on a QoQ basis from -$8.6 million in Q4 2019.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Asset Writedowns and Impairment (2009 - 2025) Analysis & Trends
Vertex Pharmaceuticals has reported Asset Writedowns and Impairment for 10 years, with the latest figure at $379.0 million in Q1 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $379.0 million in Q1 2025; TTM through Dec 2025 was $379.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $379.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $379.0 million for Q1 2025 at Vertex Pharmaceuticals, up from -$8.6 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $379.0 million in Q1 2025, with the low at $379.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 379.00 Mn |
| Dec 31, 2019 | -8.65 Mn |
| Sep 30, 2019 | 1.61 Mn |
| Jun 30, 2019 | 5.77 Mn |
| Mar 31, 2019 | 1.27 Mn |
| Dec 31, 2018 | 15.91 Mn |
| Sep 30, 2017 | 255.34 Mn |
| Dec 31, 2015 | 2.49 Mn |
| Dec 31, 2014 | 711,000.00 |
| Dec 31, 2013 | 250.60 Mn |
| Mar 31, 2013 | 412.90 Mn |
| Sep 30, 2011 | 105.80 Mn |
| Mar 31, 2010 | 624,000.00 |
| Dec 31, 2009 | 7.20 Mn |
| Jun 30, 2009 | 3.50 Mn |